Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AdiaVita is an investigational regenerative biologic product developed by Adia Med. It is described in registered clinical studies as a preparation of umbilical cord blood-derived stem cells and exosomes, administered intravenously. The product is being evaluated alone or alongside glutathione in early-stage studies for autism spectrum disorder, chronic kidney disease, and chronic mechanical lower back pain. Its precise cellular composition, exosome characterization, potency assay, and target-specific mechanism of action have not been publicly established. AdiaVita is not an approved therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on AdiaVita.